Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice

• DOI: 10.1002/ehf2.13219
• Publication Date: 2021-03-20T08:40:55Z
• Authors: Marie Pieronne‐De...; Alexandre Guéret; Zoubir Djerada; Clément Crochemore; Najah Harouki; Jean‐Paul Henry; Anaïs Dumesnil; Marine Larchevêque; Jean‐Claude do Rego; Jean‐Luc do Rego; Lionel Nicol; Vincent Richard; Frédéric Jaisser; Peter Kolkhof; Paul Mulder; Christelle Monteil; Antoine Ouvrard‐P...
• Keywords: Exercise Tolerance; [SDV]Life Sciences [q-bio]; Mineralocorticoid receptor; Ovariectomy; 610; Metabolic syndrome; 3. Good health; [SDV] Life Sciences [q-bio]; Mice; 03 medical and health sciences; Receptors, Mineralocorticoid; 0302 clinical medicine; RC666-701; Original Research Articles; 616; Diastolic dysfunction; Diseases of the circulatory (Cardiovascular) system; Animals; Female; Menopause; Naphthyridines; Aldosterone; Exercise; Mineralocorticoid Receptor Antagonists

In post-menopausal women, incidence of heart failure with preserved ejection fraction is higher than in men. Hormonal replacement therapies did not demonstrate benefits. We tested whether the non-steroidal mineralocorticoid receptor antagonist finerenone limits progression ovariectomized (OVX) mice metabolic disorders.